Pluristem Therapeutics, Inc. (PSTI) Shares Active after Upgrade at Zacks Investment Research

Pluristem Therapeutics, Inc. (NASDAQ: PSTI) shares fell back in value on Wednesday January 18 on heavier trade volume than normal after a number of analysts weighed in on the investing value of the stock with a upgraded rating.

Meanwhile, in early trade today, the S&P 500 SPX, +0.00% was off 2 points, or 0.1%, at 2,265, shortly after open. The Nasdaq Composite COMP, +0.20% was flat at 5,537. The Dow Jones Industrial Average DJIA, -0.20% slipped 54 points or 0.3%, to 19,770.

Analysts at Zacks Investment Research upgraded shares of Pluristem Therapeutics, Inc. (NASDAQ: PSTI) from Sell to Hold today. With a rating of Hold on the stock, Pluristem Therapeutics, Inc. has a 52-week high of $1.85. A number of other analysts have issued reports on the company in recent days, and the company has earned a consensus one-year price target of $3.25, above the opening price of $1.53. Usually, after analysts issue an upgrade report on a stock, they will later issue sporadic updates, usually followed by a price target change.

Yesterday Pluristem Therapeutics, Inc. (NASDAQ: PSTI) shares last traded at $1.50, which is a decrease of $0.05 from the previous closing price. Opening at $1.53, they fluctuated from $1.48 and $1.53 throughout the day.

Pluristem Therapeutics, Inc. (NASDAQ: PSTI) currently has a market cap of 121.53M.

Pluristem Therapeutics, Inc. (NASDAQ: PSTI) Average Daily Trading Volume

137,430 shares traded hands yesterday, 42 percent above normal, out of a total float 74,990,000. higher than normal. Significant increases in trading volume and price appreciation together could signal heavy volume accumulation by institutional investors.

As with all potential breakouts, investors look for volume to be at least 40%-50% higher than normal on the breakout to show that fund managers and other professional investors are jumping in.

Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.

These professional investors have teams of analysts researching thousands of stocks, so it is good corroboration to see them buying a stock you’re considering.

Pluristem Therapeutics, Inc. (NASDAQ: PSTI) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By tracking the activity of these professional investors—and the moving averages they affect—it allows for traders to make more effective decisions on trades.

Trades for Pluristem Therapeutics, Inc. (NASDAQ: PSTI) have ranged from $0.71 – 1.85, and the stock now has a 50-day MA of $1.51 and 200-day MA of $1.55. Today’s last price is 18.92%% lower than the 52 week high of $1.85.

Earnings growth is an important factor to research when investing in stocks and investors identify companies that have raised their earnings by at least 25% over the past 3 years.

DISCLOSURE: The views and opinions expressed in this article do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *